Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy

Clin Infect Dis. 2010 May 15;50(10):1419-21. doi: 10.1086/652149.

Abstract

We assessed the risk of clinically significant drug interactions in patients receiving antiretrovirals, and their recognition by physicians. Clinically significant drug interactions were recorded in 27% of 159 patients, with 15% of interactions potentially lowering antiretroviral concentrations. Risk of clinically significant drug interactions was significantly related to receipt of protease inhibitors. Only 36% of clinically significant drug interactions were correctly identified by physicians.

MeSH terms

  • Adult
  • Aged
  • Anti-HIV Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active*
  • Drug Interactions
  • Female
  • HIV Infections / drug therapy*
  • Health Services Research
  • Humans
  • Male
  • Middle Aged
  • Risk Assessment*
  • Young Adult

Substances

  • Anti-HIV Agents